Influence of peripheral artery disease and statin therapy on apolipoprotein profiles

Andrew W Gardner, Petar Alaupovic, Donald E Parker, Polly S Montgomery, Omar L Esponda, Ana I Casanegra, Andrew W Gardner, Petar Alaupovic, Donald E Parker, Polly S Montgomery, Omar L Esponda, Ana I Casanegra

Abstract

Apolipoprotein B is a stronger predictor of myocardial infarction than LDL cholesterol, and it is inversely related to physical activity and modifiable with exercise training. As such, apolipoprotein measures may be of particular relevance for subjects with PAD and claudication. We compared plasma apolipoprotein profiles in 29 subjects with peripheral artery disease (PAD) and intermittent claudication and in 39 control subjects. Furthermore, we compared the plasma apolipoprotein profiles of subjects with PAD either treated (n = 17) or untreated (n = 12) with statin medications. For the apolipoprotein subparticle analyses, subjects with PAD had higher age-adjusted Lp-B:C (P < 0.05) and lower values of Lp-A-I:A-II (P < 0.05) than controls. The PAD group taking statins had lower age-adjusted values for apoB (P < 0.05), Lp-A-II:B:C:D:E (P < 0.05), Lp-B:E + Lp-B:C:E (P < 0.05), Lp-B:C (P < 0.05), and Lp-A-I (P < 0.05) than the untreated PAD group. Subjects with PAD have impaired apolipoprotein profiles than controls, characterized by Lp-B:C and Lp-A-I:A-II. Furthermore, subjects with PAD on statin medications have a more favorable risk profile, particularly noted in multiple apolipoprotein subparticles. The efficacy of statin therapy to improve cardiovascular risk appears more evident in the apolipoprotein sub-particle profile than in the more traditional lipid profile of subjects with PAD and claudication. This trial is registered with ClinicalTrials.gov NCT00618670.

References

    1. Roger VL, Go AS, Lloyd-Jones DM, et al. Executive summary: heart disease and stroke statistics—2012 update: a report from the American heart association. Circulation. 2012;125(1):188–197.
    1. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113(11):e463–e654.
    1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR. Inter-society consensus for the management of peripheral arterial disease (TASC II) Journal of Vascular Surgery. 2007;45(1):S5–S67.
    1. Brass EP, Hiatt WR. Review of mortality and cardiovascular event rates in patients enrolled in clinical trials for claudication therapies. Vascular Medicine. 2006;11(3):141–145.
    1. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. The New England Journal of Medicine. 1992;326(6):381–386.
    1. Hirsch AT, Hartman L, Town RJ, Virnig BA. National health care costs of peripheral arterial disease in the Medicare population. Vascular Medicine. 2008;13(3):209–215.
    1. Gardner AW, Skinner JS, Cantwell BW, Smith LK. Progressive vs single-stage treadmill tests for evaluation of claudication. Medicine & Science in Sports & Exercise. 1991;23(4):402–408.
    1. Hiatt WR, Nawaz D, Regensteiner JG, Hossack KF. The evaluation of exercise performance in patients with peripheral vascular disease. Journal of Cardiopulmonary Rehabilitation and Prevention. 1988;12:525–532.
    1. McDermott MM, Greenland P, Liu K, et al. Leg symptoms in peripheral arterial disease associated clinical characteristics and functional impairment. Journal of the American Medical Association. 2001;286(13):1599–1606.
    1. McDermott MM, Liu K, Greenland P, et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. Journal of the American Medical Association. 2004;292(4):453–461.
    1. McDermott MM, Liu K, O’Brien E, et al. Measuring physical activity in peripheral arterial disease: a comparison of two physical activity questionnaires with an accelerometer. Angiology. 2000;51(2):91–100.
    1. Sieminski DJ, Gardner AW. The relationship between free-living daily physical activity and the severity of peripheral arterial occlusive disease. Vascular Medicine. 1997;2(4):286–291.
    1. Ware JE., Jr. The status of health assessment 1994. Annual Review of Public Health. 1995;16:327–354.
    1. McDermott MM, Guralnik JM, Tian L, et al. Baseline functional performance predicts the rate of mobility loss in persons with peripheral arterial disease. Journal of the American College of Cardiology. 2007;50(10):974–982.
    1. Fried LP, Guralnik JM. Disability in older adults:evidence regarding significance, etiology, and risk. Journal of the American Geriatrics Society. 1997;45(1):92–100.
    1. Afaq A, Montgomery PS, Scott KJ, Blevins SM, Whitsett TL, Gardner AW. The effect of hypercholestrolemia on calf muscle hemoglobin oxygen saturation in patients with intermittent claudication. Angiology. 2008;59(5):534–541.
    1. Gardner AW, Montgomery PS. The effect of metabolic syndrome components on exercise performance in patients with intermittent claudication. Journal of Vascular Surgery. 2008;47(6):1251–1258.
    1. Yusuf PS, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet. 2004;364(9438):937–952.
    1. Simonsson M, Schmidt C, Sigurdadottir V, Helenius M-L, Fagerberg B. Life style habits such as alcohol consumption and physical activity in relation to serum apoB/apoA-I ratio amongst 64-year-old women with varying degrees of glucose tolerance. Journal of Internal Medicine. 2007;262(5):537–544.
    1. Holme I, Høstmark AT, Anderssen SA. ApoB but not LDL-cholesterol is reduced by exercise training in overweight healthy men. Results from the 1-year randomized Oslo Diet and Exercise Study. Journal of Internal Medicine. 2007;262(2):235–243.
    1. Gardner AW, Parker DE, Montgomery PS, Scott KJ, Blevins SM. Efficacy of quantified home-based exercise and supervised exercise in patients with intermittent claudication: a randomized controlled trial. Circulation. 2011;123(5):491–498.
    1. Gardner AW, Montgomery PS, Scott KJ, Afaq A, Blevins SM. Patterns of ambulatory activity in subjects with and without intermittent claudication. Journal of Vascular Surgery. 2007;46(6):1208–1214.
    1. Alaupovic P. Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins. Methods in Enzymology. 1996;263:32–60.
    1. Alaupovic P. The concept of apolipoprotein-defined lipoprotein families and its clinical significance. Current Atherosclerosis Reports. 2003;5(6):459–467.
    1. McConathy WJ, Greenhalgh RM, Alaupovic P. Plasma lipid and apolipoprotein profiles of women with two types of peripheral arterial disease. Atherosclerosis. 1984;50(3):295–306.
    1. McConathy WJ, Alaupovic P, Woolcock N, Laing SP, Powell J, Greenhalgh R. Lipids and apolipoprotein profiles in men with aneurysmal and stenosing aorto-iliac atherosclerosis. European Journal of Vascular Surgery. 1989;3(6):511–514.
    1. McDermott MM, Guralnik JM, Greenland P, et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation. 2003;107(5):757–761.
    1. Criqui MH, Denenberg JO, Bird CE, Fronek A, Klauber MR, Langer RD. The correlation between symptoms and non-invasive test results in patient referred for peripheral arterial disease testing. Vascular Medicine. 1996;1(1):65–71.
    1. Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clinical Chemistry. 1982;28(6):1379–1388.
    1. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry. 1972;18(6):499–502.
    1. Warnick GR, Albers JJ. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. Journal of Lipid Research. 1978;19(1):65–76.
    1. Wang C-S, Alaupovic P, Gregg RE, Brewer HB., Jr. Studies on the mechanism of hypertriglyceridemia in Tangier disease. Determination of plasma lipolytic activities, k1 values and apolipoprotein composition of the major lipoprotein density classes. Biochimica et Biophysica Acta. 1987;920(1):9–19.
    1. Riepponen P, Marniemi J, Rautaoja T. Immunoturbidimetric determination of apolipoproteins A-1 and B in serum. Scandinavian Journal of Clinical and Laboratory Investigation. 1987;47(7):739–744.
    1. Marz W, Trommlitz M, Gross W. Differential turbidimetric assay for subpopulations of lipoproteins containing apolipoprotein A-I. Zeitschrift fur klinische Chemie und klinische Biochemie. 1988;26(9):573–578.
    1. Alaupovic P. Apolipoprotein composition as the basis for classifying plasma lipoproteins: characterization of ApoA- and ApoB-containing lipoprotein families. Progress in Lipid Research. 1991;30(2-3):105–138.
    1. Curry MD, McConathy WJ, Fesmire JD, Alaupovic P. Quantitative determination of human apolipoprotein C-III by electroimmunoassay. Biochimica et Biophysica Acta. 1980;617(3):503–513.
    1. Gervaise N, Garrigue MA, Lasfargues G, Lecomte P. Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in Type II diabetes. Diabetologia. 2000;43(6):703–708.
    1. Alaupovic P, Wang C-S, McConathy WJ. Lipolytic degradation of human very low density lipoproteins by human milk lipoprotein lipase: the identification of lipoprotein B as the main lipoprotein degradation product. Archives of Biochemistry and Biophysics. 1986;244(1):226–237.
    1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) Journal of the American Medical Association. 2001;285(19):2486–2497.
    1. Gardner AW, Montgomery PS, Parker DE. Metabolic syndrome impairs physical function, health-related quality of life, and peripheral circulation in patients with intermittent claudication. Journal of Vascular Surgery. 2006;43(6):1191–1196.
    1. Behre C, Bergström G, Schmidt C. Moderate physical activity is associated with lower ApoB/ApoA-I ratios independently of other risk factors in healthy, middle-aged men. Angiology. 2010;61(8):775–779.
    1. Schillinger M, Exner M, Mlekusch W, et al. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. European Heart Journal. 2004;25(9):742–748.
    1. Mohler ER, III, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 2003;108(12):1481–1486.
    1. Alaupovic P, Heinonen T, Shurzinske L, Black DM. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels. Atherosclerosis. 1997;133(1):123–133.
    1. Nael R, Montgomery PS, Scott KJ, Blevins SM, Gardner AW. Gender differences in the prevalence and management of metabolic syndrome and its components in patients with peripheral artery disease. Angiology. 2011;62(8):657–661.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera